Article Text

Download PDFPDF

444 The use of sentinellymphnodebiopsy in the treatment of breastductalcarcinoma in situ
  1. S Sakhri,
  2. O Jaidane,
  3. M Bouheni,
  4. I Bouraoui,
  5. M Slimane and
  6. K Rahal
  1. Slah Azaiez institut, surgicaldepartment, Tunis,Tunisia, Tunisia


Introduction Withimprovements to the breast cancer screening program, more and more womenwithductalcarcinoma in situ (DCIS) are beingdiagnosed and treated. However, the axillarytreatment of patients with DCIS remainscontroversial. These patients, whoexhibitpre-invasive tumorswith no invasive component, are theoreticallybelieved to have no chance of lymphnodemetastases.

Material and Methods itis a retrospectivestudycarried out at the institute of Salah AziezTunisiawhichincluded 243 patients presentedwith the final pathology of DCIS, over a period of 22 yearsbetween the years 1993 and 2014.

Results 243 patients presentedwith the final pathology of DCIS, 18,10% of patients underwentsentinellymphnodebiopsy (SLNB). A total of 61 (25%) patients underwentbreast-conservingsurgery (BCS), and 182 (75%) underwentmastectomy, of which 0,82% and 17,28% respectivelyhad a concomitant SLNB. all the lymphnodessampledwere not metastatic. The colorimetricmethodweredonein 34,09%, the scintigraphicmethod (45,45%) and the use of the twomethodis about 68,18%.

In the post opérative, no complication wasseen in this patients, howeverthe patients whohad anlymphnode dissectionhad a complications lik : Lymphe Dema and lymphocele

Conclusion The rates of SLNB positivity in pure DCIS are verylow, and thereiscontinuinguncertainty about itsclinical importance.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.